Key Documents

Hannah Valantine

Professor - Med Center Line, Medicine - Cardiovascular Medicine
Member, Cancer Center

Contact Information

Clinical Offices

Cardiovascular Medicine Clinic 300 Pasteur Dr A260 MC 5319 Stanford, CA 94305-2200
Telephone Work (650) 723-6459 Fax (650) 723-8392
Academic Offices

Personal Information
Email hvalantine@stanford.edu Tel (650) 724-0239, (650) 723-2665

Administrative Contact
Lydia Espinosa Administrative Associate Email lydiae@stanford.edu Tel Work 650-724-0239

Not for medical emergencies or patient use

Clinical Focus

Cardiology (Heart)
Cardiovascular Medicine
Heart and Lung Transplantation

Administrative Appointments

President, Western State Affiliation, American Heart Association , (2004– present )
Senior Associate Dean for Diversity and Faculty Development, School of Medicine , (2005– present )

Professional Education

SUMC - Graduate Medical Education (1986) CA
Hammersmith Hospital (1984) England
Brompton Hospital (1982) UK
Board Certification: Internal Medicine, Royal College of Physicians-U.K. (1981)
St. George's Hospital Medical School (1981) England
St. Georges'S & Kingston Hosp (1979) UK
St. George's Hospital Medical School (1978) England
MBBS, St Georges Hosp/London Univ, UK Medicine (MD equivalent) (1978)
MRCP, London University, London, UK Internal Medicine (1982)
Registrar, Hammersmith Hospital, London, UK Cardiology Fellow (1984)
Fellow, Stanford University Cardiology (1986)
MD, London University, London, UK Cardiology (PhD equivalent) (1988)

Research Interests

My lab is focused on understanding the mechanism mediating acute and chronic allograft failure, in particular on the role of microvascular injury in acute allograft failure and the mechanisms of mediating transplant coronary artery disease.

1. Role of microvascular injury in acute allograft failure. We observed decreased cardiac allograft function in patients to be significantly associated with loss of microvascular cell surface markers, consistent with altered biology of the vascular endothelium or injury, and with up-regulation of cytokines such as IL-6, IL-10, TGF-b, and TNF-a. Decreased cardiac allograft function, in particular diastolic dysfunction, was highly predictive of allograft vascular disease and poor outcome in long-term patients. To further characterize cellular and molecular mechanisms we developed quantitative methods to monitor allograft function and correlate it with cytokine expression in a rat heterotopic transplant model. We developed echocardiographic markers of systolic and diastolic function and found decreasing systolic and diastolic function highly correlated with up-regulation of IL-6 expression. Correlation with other key cytokines is now being examined. Future studies will determine if up-regulation of cytokine expression occurs in vascular endothelial cells or endogenous cells of the graft vs. infiltrating mononuclear cells. We will then inhibit transcription genes and block translation with cytokine monoclonal antibodies.

2. Mechanisms mediating allograft dysfunction. We observed the major risk factors for transplant atherosclerosis in patients to be metabolic (hyperglycemia, hypertriglyceridemia, and low HDL). To further study cellular and molecular mechanisms mediating this process, we recapitulated metabolic abnormalities in the rat heart transplant model and confirmed rapid development of transplant atherosclerosis. Later we will characterize the cytokines involved in metabolically deranged animals which develop rapid atherosclerosis, and examine the relative contributions of hyperlipidemia, hyperglycemia, and alloimmunity in this new model of transplant atherosclerosis.

Publications

Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus. Potena L, Fearon WF, Sydow K, Holweg C, Luikart H, Chin C, Weisshaar D, Mocarski ES, Lewis DB, Valantine HA, Cooke JP. Transplantation. 2008; 85 (6): 827-33
Twenty-year survivors of heart transplantation at Stanford University. Deuse T, Haddad F, Pham M, Hunt S, Valantine H, Bates MJ, Mallidi HR, Oyer PE, Robbins RC, Reitz BA. Am J Transplant. 2008; 8 (9): 1769-74
Effect of rapamycin therapy on coronary artery physiology early after cardiac transplantation. Sinha SS, Pham MX, Vagelos RH, Perlroth MG, Hunt SA, Lee DP, Valantine HA, Yeung AC, Fearon WF. Am Heart J. 2008; 155 (5): 889.e1-6
Interplay between systemic inflammation and markers of insulin resistance in cardiovascular prognosis after heart transplantation. Biadi O, Potena L, Fearon WF, Luikart HI, Yeung A, Ferrara R, Hunt SA, Mocarski ES, Valantine HA. J Heart Lung Transplant. 2007; 26 (4): 324-30
Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis. Potena L, Holweg CT, Vana ML, Bashyam L, Rajamani J, McCormick AL, Cooke JP, Valantine HA, Mocarski ES. J Clin Microbiol. 2007; 45 (6): 1804-10
Changes in coronary arterial dimensions early after cardiac transplantation. Fearon WF, Potena L, Hirohata A, Sakurai R, Yamasaki M, Luikart H, Lee J, Vana ML, Cooke JP, Mocarski ES, Yeung AC, Valantine HA. Transplantation. 2007; 83 (6): 700-5
Pulmonary nocardiosis in a heart transplant patient: case report and review of the literature. Haddad F, Hunt SA, Perlroth M, Valantine H, Doyle R, Montoya J. J Heart Lung Transplant. 2007; 26 (1): 93-7
Determinants of lumen loss between years 1 and 2 after cardiac transplantation. Sakurai R, Yamasaki M, Nakamura M, Hirohata A, Honda Y, Bonneau HN, Luikart H, Yock PG, Fitzgerald PJ, Yeung AC, Valantine HA, Fearon WF. Transplantation. 2007; 84 (9): 1097-102
Cytomegalovirus-associated allograft rejection in heart transplant patients. Potena L, Valantine HA. Curr Opin Infect Dis. 2007; 20 (4): 425-31
Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. Kuppahally SS, Valantine HA, Weisshaar D, Parekh H, Hung YY, Haddad F, Fowler M, Vagelos R, Perlroth MG, Robbins RC, Hunt SA. Am J Transplant. 2007; 7 (10): 2388-95
Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial. Pham MX, Deng MC, Kfoury AG, Teuteberg JJ, Starling RC, Valantine H. J Heart Lung Transplant. 2007; 26 (8): 808-14
Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. Valantine H, J Heart Lung Transplant. 2007; 26 (6): 557-64
Changes in coronary anatomy and physiology after heart transplantation. Hirohata A, Nakamura M, Waseda K, Honda Y, Lee DP, Vagelos RH, Hunt SA, Valantine HA, Yock PG, Fitzgerald PJ, Yeung AC, Fearon WF. Am J Cardiol. 2007; 99 (11): 1603-7
Validation of a screening protocol for identifying low-risk candidates with type 1 diabetes mellitus for kidney with or without pancreas transplantation. Ma IW, Valantine HA, Shibata A, Waskerwitz J, Dafoe DC, Alfrey EJ, Tan JC, Millan M, Busque S, Scandling JD. Clin Transplant. 2006 Mar-Apr; 20 (2): 139-46
Giant coronary aneurysms in heart transplantation: an unusual presentation of cardiac allograft vasculopathy. Haddad F, Perez M, Fleischmann D, Valantine H, Hunt SA. J Heart Lung Transplant. 2006; 25 (11): 1367-70
T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Tu W, Potena L, Stepick-Biek P, Liu L, Dionis KY, Luikart H, Fearon WF, Holmes TH, Chin C, Cooke JP, Valantine HA, Mocarski ES, Lewis DB. Circulation. 2006; 114 (15): 1608-15
Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Potena L, Holweg CT, Chin C, Luikart H, Weisshaar D, Narasimhan B, Fearon WF, Lewis DB, Cooke JP, Mocarski ES, Valantine HA. Transplantation. 2006; 82 (3): 398-405
Discordant changes in epicardial and microvascular coronary physiology after cardiac transplantation: Physiologic Investigation for Transplant Arteriopathy II (PITA II) study. Fearon WF, Hirohata A, Nakamura M, Luikart H, Lee DP, Vagelos RH, Hunt SA, Valantine HA, Fitzgerald PJ, Yock PG, Yeung AC. J Heart Lung Transplant. 2006; 25 (7): 765-71
Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Kuppahally S, Al-Khaldi A, Weisshaar D, Valantine HA, Oyer P, Robbins RC, Hunt SA. Am J Transplant. 2006; 6 (5 Pt 1): 986-92
Recurrence of iron deposition in the cardiac allograft in a patient with non-HFE hemochromatosis. Kuppahally SS, Hunt SA, Valantine HA, Berry GJ. J Heart Lung Transplant. 2006; 25 (1): 144-7
Peripheral blood leukocyte counts in cytomegalovirus infected heart transplant patients: impact of acute disease versus subclinical infection. Cooke ME, Potena L, Luikart H, Valantine HA. Transplantation. 2006; 82 (11): 1419-24
Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Chin C, Pittson S, Luikart H, Bernstein D, Robbins R, Reitz B, Oyer P, Valantine H. Transplantation. 2005; 80 (4): 477-81
Certican (Everolimus) in heart transplantation: from clinical trial to clinical experience. Proceedings of a meeting, Vienna, Austria, September 9, 2004. J Heart Lung Transplant. 2005; 24 (4 Suppl): S183-211
From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. Valantine H, Zuckermann A. J Heart Lung Transplant. 2005; 24 (4 Suppl): S185-90; discussion S210-1
Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial. Valantine H, J Heart Lung Transplant. 2005; 24 (4 Suppl): S191-5; discussion S210-1
Use of the implantable cardioverter-defibrillator in long-term survivors of orthotopic heart transplantation. Ptaszek LM, Wang PJ, Hunt SA, Valantine H, Perlroth M, Al-Ahmad A. Heart Rhythm. 2005; 2 (9): 931-3
Cardiac allograft vasculopathy after heart transplantation: risk factors and management. Valantine H, J Heart Lung Transplant. 2004; 23 (5 Suppl): S187-93
Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. Kato T, Chan MC, Gao SZ, Schroeder JS, Yokota M, Murohara T, Iwase M, Noda A, Hunt SA, Valantine HA. J Am Coll Cardiol. 2004; 43 (6): 1034-41
The role of viruses in cardiac allograft vasculopathy. Valantine HA, Am J Transplant. 2004; 4 (2): 169-77
Analysis of survivors more than 10 years after heart transplantation in the cyclosporine era: Stanford experience. Shiba N, Chan MC, Kwok BW, Valantine HA, Robbins RC, Hunt SA. J Heart Lung Transplant. 2004; 23 (2): 155-64
Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Weis M, Kledal TN, Lin KY, Panchal SN, Gao SZ, Valantine HA, Mocarski ES, Cooke JP. Circulation. 2004; 109 (4): 500-5
Longer-term risks associated with 10-year survival after heart transplantation in the cyclosporine era. Shiba N, Chan MC, Valantine HA, Gao SZ, Robbins RC, Hunt SA. J Heart Lung Transplant. 2003; 22 (10): 1098-106
Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". Valantine HA, Transplantation. 2003; 76 (6): 891-9
Post-operative conversion from cyclosporine to tacrolimus in heart transplantation: a single-center experience. Cantin B, Kwok BW, Shiba N, Valantine HA, Hunt SA, Chan MC. J Heart Lung Transplant. 2003; 22 (7): 723-30
Preferential involvement of larger vessels in a rat model of diabetes-induced graft vasculopathy. Cantin B, Zhu D, Wen P, Panchal SN, Gwathmey JK, Reaven GM, Valantine HA. J Heart Lung Transplant. 2002; 21 (9): 1040-3
Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection. Chan MC, Kwok BW, Shiba N, Cantin B, Valantine HA, Hunt SA. Transplant Proc. 2002; 34 (5): 1850-2
Reversal of diabetes-induced rat graft transplant coronary artery disease by metformin. Cantin B, Zhu D, Wen P, Panchal SN, Dai X, Gwathmey JK, Reaven GM, Valantine HA. J Heart Lung Transplant. 2002; 21 (6): 637-43
Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection. Cantin B, Giannetti N, Parekh H, Panchal SN, Kwok BW, Najem R, Woodman K, Hunt SA, Valantine HA. Clin Transplant. 2002; 16 (3): 196-201
Detection of early atherosclerosis with radiolabeled monocyte chemoattractant protein-1 in prediabeteic Zucker rats. Blankenberg FG, Wen P, Dai M, Zhu D, Panchal SN, Tait JF, Post AM, Strauss HW, Valantine HA. Pediatr Radiol. 2001; 31 (12): 827-35
Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Valantine HA, Luikart H, Doyle R, Theodore J, Hunt S, Oyer P, Robbins R, Berry G, Reitz B. Transplantation. 2001; 72 (10): 1647-52
Transplant coronary artery disease: a novel model independent of cellular alloimmune response. Cantin B, Wen P, Zhu D, Dai M, Panchal SN, Billingham ME, Gwathmey JK, Valantine HA. Circulation. 2001; 104 (21): 2615-9
Mild hyperhomocysteinemia is not associated with cardiac allograft coronary disease. Giannetti N, Herity NA, Alimollah A, Gao SZ, Schroeder JS, Yeung AC, Hunt SA, Valantine HA. Clin Transplant. 2001; 15 (4): 247-52
Detection and treatment of coronary artery disease in liver transplant candidates. Keeffe BG, Valantine H, Keeffe EB. Liver Transpl. 2001; 7 (9): 755-61
Severe tricuspid regurgitation after heart transplantation. Chan MC, Giannetti N, Kato T, Kornbluth M, Oyer P, Valantine HA, Robbins RC, Hunt SA. J Heart Lung Transplant. 2001; 20 (7): 709-17
Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Valantine H, Rickenbacker P, Kemna M, Hunt S, Chen YD, Reaven G, Stinson EB. Circulation. 2001; 103 (17): 2144-52
Impact of type 1 diabetes on microvascular vs. macrovascular involvement with TXCAD: is there a difference in models of the disease? Valantine H, Zhu D, Wen P, Panchal SN, Dai X. J Heart Lung Transplant. 2001; 20 (2): 186-187
Neoral use in the cardiac transplant recipient. Valantine H, Transplant Proc. 2000; 32 (3A Suppl): 27S-44S
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P, Stinson EB, Brown BW, Merigan TC, Schroeder JS. Circulation. 1999; 100 (1): 61-6
Role of CMV in transplant coronary artery disease and survival after heart transplantation. Valantine HA, Transpl Infect Dis. 1999; 1 Suppl 1 25-30
Scedosporium apiospermum (Pseudallescheria boydii) infection in a heart transplant recipient: a case of mistaken identity. Lopez FA, Crowley RS, Wastila L, Valantine HA, Remington JS. J Heart Lung Transplant. 1998; 17 (3): 321-4
Diabetes and dyslipidemia. A new model for transplant coronary artery disease. Hoang K, Chen YD, Reaven G, Zhang L, Ross H, Billingham M, Valantine H. Circulation. 1998; 97 (21): 2160-8
Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Reichenspurner H, Gamberg P, Nitschke M, Valantine H, Hunt S, Oyer PE, Reitz BA. Transplant Proc. 1997 Feb-Mar; 29 (1-2): 627-8
Individualizing immunosuppression for heart transplantation: strategies for the next decade. Valantine HA, Transplant Proc. 1997; 29 (8A): 5S-8S
Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study. Ross HJ, Gullestad L, Pak J, Slauson S, Valantine HA, Hunt SA. J Heart Lung Transplant. 1997; 16 (2): 179-89
Importance of decreased heart rate in predicting transplant coronary artery disease. Gullestad L, Ross H, Myers J, Hoang K, Hunt S, Stinson EB, Valantine HA. Clin Transplant. 1997; 11 (6): 628-32
Heart transplantation in patients over 54 years of age. Mortality, morbidity and quality of life. Rickenbacher PR, Lewis NP, Valantine HA, Luikart H, Stinson EB, Hunt SA. Eur Heart J. 1997; 18 (5): 870-8
Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. Lewis NP, Tsao PS, Rickenbacher PR, Xue C, Johns RA, Haywood GA, von der Leyen H, Trindade PT, Cooke JP, Hunt SA, Billingham ME, Valantine HA, Fowler MB. Circulation. 1996; 93 (4): 720-9
Early Doppler echocardiographic dysfunction is associated with an increased mortality after orthotopic cardiac transplantation. Ross HJ, Gullestad L, Hunt SA, Tovey DA, Puryear JB, McMillan A, Stinson EB, Valantine HA. Circulation. 1996; 94 (9 Suppl): II289-93
Volume-mediated pulmonary responses in liver transplant candidates. Kuo PC, Schroeder RA, Vagelos RH, Valantine H, Garcia G, Alfrey EJ, Haddow G, Dafoe DC. Clin Transplant. 1996; 10 (6 Pt 1): 521-7
Coronary artery intimal thickening in the transplanted heart. An in vivo intracoronary untrasound study of immunologic and metabolic risk factors. Rickenbacher PR, Kemna MS, Pinto FJ, Hunt SA, Alderman EL, Schroeder JS, Stinson EB, Popp RL, Chen I, Reaven G, Valantine HA. Transplantation. 1996; 61 (1): 46-53
Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound Transplant Study Group. Yeung AC, Davis SF, Hauptman PJ, Kobashigawa JA, Miller LW, Valantine HA, Ventura HO, Wiedermann J, Wilensky R. J Heart Lung Transplant. 1995 Nov-Dec; 14 (6 Pt 2): S215-20
Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound. Valantine HA, J Heart Lung Transplant. 1995 Nov-Dec; 14 (6 Pt 2): S234-7
Distribution and morphologic features of coronary artery disease in cardiac allografts: an intracoronary ultrasound study. Chenzbraun A, Pinto FJ, Alderman EL, Botas J, Oesterle SN, Schroeder JS, Valantine H, Popp RL. J Am Soc Echocardiogr. 1995 Jan-Feb; 8 (1): 1-8
Magnetic resonance imaging-derived parameter of portal flow predicts volume-mediated pulmonary hypertension in liver transplantation candidates. Kuo PC, Alfrey EJ, Li K, Vagelos R, Valantine H, Garcia G, Dafoe DC. Surgery. 1995; 118 (4): 685-91; discussion 691-2
Correlation of donor characteristics with transplant coronary artery disease as assessed by intracoronary ultrasound and coronary angiography. Rickenbacher PR, Pinto FJ, Lewis NP, Hunt SA, Gamberg P, Alderman EL, Schroeder JS, Valantine HA. Am J Cardiol. 1995; 76 (5): 340-5
Clinical outcome of interval cadaveric renal transplantation in cardiac allograft recipients. Kuo PC, Luikart H, Busse-Henry S, Hunt SA, Valantine HA, Stinson EB, Oyer PE, Scandling JD, Alfrey EJ, Dafoe DC. Clin Transplant. 1995; 9 (2): 92-7
Cardiac allograft vascular disease. Relationship to microvascular cell surface markers and inflammatory cell phenotypes on endomyocardial biopsy. Deng MC, Bell S, Huie P, Pinto F, Hunt SA, Stinson EB, Sibley R, Hall BM, Valantine HA. Circulation. 1995; 91 (6): 1647-54
Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. Rickenbacher PR, Pinto FJ, Chenzbraun A, Botas J, Lewis NP, Alderman EL, Valantine HA, Hunt SA, Schroeder JS, Popp RL. J Am Coll Cardiol. 1995; 25 (1): 171-7
Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Rickenbacher PR, Pinto FJ, Lewis NP, Hunt SA, Alderman EL, Schroeder JS, Stinson EB, Brown BW, Valantine HA. Circulation. 1995; 92 (12): 3445-52
Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Wagner JA, Ross H, Hunt S, Gamberg P, Valantine H, Merigan TC, Stinson EB. Transplantation. 1995; 60 (12): 1473-7
The relationship of granzyme A and perforin expression to cardiac allograft rejection and dysfunction. Alpert S, Lewis NP, Ross H, Fowler M, Valantine HA. Transplantation. 1995; 60 (12): 1478-85
Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. Valantine HA, Transplant Proc. 1995; 27 (5 Suppl 1): 49-57
Exercise echocardiography in heart transplant recipients: a comparison with angiography and intracoronary ultrasonography. Collings CA, Pinto FJ, Valantine HA, Popylisen S, Puryear JV, Schnittger I. J Heart Lung Transplant. 1994 Jul-Aug; 13 (4): 604-13
Metabolic risk factors for atherosclerosis in heart transplant recipients. Kemna MS, Valantine HA, Hunt SA, Schroeder JS, Chen YD, Reaven GM. Am Heart J. 1994; 128 (1): 68-72
Cardiac transplantation: the Stanford experience in the cyclosporine era. Sarris GE, Moore KA, Schroeder JS, Hunt SA, Fowler MB, Valantine HB, Vagelos RH, Billingham ME, Oyer PE, Stinson EB. J Thorac Cardiovasc Surg. 1994; 108 (2): 240-51; discussion 251-2
Cytokine gene expression in human cardiac allograft recipients. Wu CJ, Kurbegov D, Lattin B, Burchard E, Finkle C, Valantine H, Billingham ME, Starnes VA, Clayberger C. Transpl Immunol. 1994; 2 (3): 199-207
Cytokines as potential mediators of acute allograft diastolic dysfunction in cyclosporine-treated patients: a pilot study using in situ hybridization. Valantine H, Johnson F, Dong C, Lewis N, Tovey D, Huie P, Pratt R, Stinson E, Hunt S, Sibley R. Transplant Proc. 1994; 26 (5): 2852-3
Feasibility of serial intracoronary ultrasound imaging for assessment of progression of intimal proliferation in cardiac transplant recipients. Pinto FJ, Chenzbraun A, Botas J, Valantine HA, St Goar FG, Alderman EL, Oesterle SN, Schroeder JS, Popp RL. Circulation. 1994; 90 (5): 2348-55
Impact of cyclosporine dose on long-term outcome after heart transplantation. Valantine H, Hunt S, Gamberg P, Miller J, Luikart H. Transplant Proc. 1994; 26 (5): 2710-2
Recovery of the right ventricle after single-lung transplantation in pulmonary hypertension. Kramer MR, Valantine HA, Marshall SE, Starnes VA, Theodore J. Am J Cardiol. 1994; 73 (7): 494-500
Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis. Gao SZ, Schroeder JS, Hunt SA, Valantine HA, Hill IR, Stinson EB. J Heart Lung Transplant. 1993 Nov-Dec; 12 (6 Pt 1): 1029-35
Intracoronary ultrasound imaging in heart transplant recipients: the Stanford experience. Valantine H, Pinto FJ, St Goar FG, Alderman EL, Popp RL. J Heart Lung Transplant. 1992 May-Jun; 11 (3 Pt 2): S60-4
Cost containment: coadministration of diltiazem with cyclosporine after heart transplantation. Valantine H, Keogh A, McIntosh N, Hunt S, Oyer P, Schroeder J. J Heart Lung Transplant. 1992 Jan-Feb; 11 (1 Pt 1): 1-7; discussion 7-8
Nitroglycerin-induced coronary vasodilation in cardiac transplant recipients. Evaluation with in vivo intracoronary ultrasound. Pinto FJ, St Goar FG, Fischell TA, Stadius ML, Valantine HA, Alderman EL, Popp RL. Circulation. 1992; 85 (1): 69-77
Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of "angiographically silent" intimal thickening. St Goar FG, Pinto FJ, Alderman EL, Valantine HA, Schroeder JS, Gao SZ, Stinson EB, Popp RL. Circulation. 1992; 85 (3): 979-87
Sensitivity and specificity of diastolic indexes for rejection surveillance: temporal correlation with endomyocardial biopsy. Valantine HA, Yeoh TK, Gibbons R, McCarthy P, Stinson EB, Billingham ME, Popp RL. J Heart Lung Transplant. 1991 Sep-Oct; 10 (5 Pt 1): 757-65
Frequency and mechanism of bradycardia in cardiac transplant recipients and need for pacemakers. DiBiase A, Tse TM, Schnittger I, Wexler L, Stinson EB, Valantine HA. Am J Cardiol. 1991; 67 (16): 1385-9
Changes in cardiac morphology and function following single-lung transplantation. Yeoh TK, Kramer MR, Marshall S, Theodore J, Gibbons R, Valantine HA, Starnes VA. Transplant Proc. 1991; 23 (1 Pt 2): 1226-7
Variability of Doppler echocardiographic indexes of left ventricular filling in transplant recipients and in normal subjects. Valantine HA, Hatle LK, Appleton CP, Gibbons R, Popp RL. J Am Soc Echocardiogr. 1990 Jul-Aug; 3 (4): 276-84
Left ventricular diastolic function. Doppler echocardiographic changes soon after cardiac transplantation. StGoar FG, Gibbons R, Schnittger I, Valantine HA, Popp RL. Circulation. 1990; 82 (3): 872-8
Serial measurement of integrated ultrasonic backscatter in human cardiac allografts for the recognition of acute rejection. Masuyama T, Valantine HA, Gibbons R, Schnittger I, Popp RL. Circulation. 1990; 81 (3): 829-39
Long-term management and results in heart transplant recipients. Valantine HA, Cardiol Clin. 1990; 8 (1): 141-8
Cardiac transplantation in patients with preexisting neoplastic diseases. Edwards BS, Hunt SA, Fowler MB, Valantine HA, Stinson EB, Schroeder JS. Am J Cardiol. 1990; 65 (7): 501-4
Recurrence of amyloid in a cardiac allograft four months after transplantation. Valantine HA, Billingham ME. J Heart Transplant. 1989 Jul-Aug; 8 (4): 337-41
Frequency of familial nature of dilated cardiomyopathy and usefulness of cardiac transplantation in this subset. Valantine HA, Hunt SA, Fowler MB, Billingham ME, Schroeder JS. Am J Cardiol. 1989; 63 (13): 959-63
Increasing pericardial effusion in cardiac transplant recipients. Valantine HA, Hunt SA, Gibbons R, Billingham ME, Stinson EB, Popp RL. Circulation. 1989; 79 (3): 603-9
Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens. Gao SZ, Schroeder JS, Alderman EL, Hunt SA, Valantine HA, Wiederhold V, Stinson EB. Circulation. 1989; 80 (5 Pt 2): III100-5
Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Circulation. 1989; 79 (3): 483-90
A hemodynamic and Doppler echocardiographic study of ventricular function in long-term cardiac allograft recipients. Etiology and prognosis of restrictive-constrictive physiology. Valantine HA, Appleton CP, Hatle LK, Hunt SA, Billingham ME, Shumway NE, Stinson EB, Popp RL. Circulation. 1989; 79 (1): 66-75
Cardiac transplantation. Valantine HA, Schroeder JS. Intensive Care Med. 1989; 15 (5): 283-9
Cardiac sarcoidosis: response to steroids and transplantation. Valantine HA, Tazelaar HD, Macoviak J, Mullin AV, Hunt SA, Fowler MB, Billingham ME, Schroeder JS. J Heart Transplant. 1987 Jul-Aug; 6 (4): 244-50
Changes in Doppler echocardiographic indexes of left ventricular function as potential markers of acute cardiac rejection. Valantine HA, Fowler MB, Hunt SA, Naasz C, Hatle LK, Billingham ME, Stinson EB, Popp RL. Circulation. 1987; 76 (5 Pt 2): V86-92